Related Experiment Video

Updated: Nov 16, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.1K

Donepezil for mild cognitive impairment in Parkinson's disease

Kyoungwon Baik1, Seon Myeong Kim2, Jin Ho Jung1

  • 1Department of Neurology, Yonsei University College of Medicine, Seoul, Republic of Korea.

Scientific Reports
|February 27, 2021
PubMed

Insights

Donepezil did not improve cognitive function in Parkinson's disease with mild cognitive impairment (PD-MCI). However, it modulated electroencephalography (EEG) patterns, suggesting EEG may be a sensitive biomarker for PD-MCI treatment effects.

Area of Science:

  • Neuroscience
  • Neurology
  • Pharmacology

Background:

  • Parkinson's disease (PD) often involves mild cognitive impairment (PD-MCI).
  • Cognitive decline significantly impacts PD patient quality of life.
  • Effective treatments for PD-MCI remain limited.

Purpose of the Study:

  • To evaluate the efficacy of donepezil in treating PD-MCI.
  • To assess donepezil's impact on cognitive function and EEG markers in PD-MCI patients.

Main Methods:

  • Prospective, open-label, two-arm study involving 80 PD-MCI patients.
  • Treatment group received donepezil for 48 weeks; control group did not.
  • Primary outcomes: Korean Mini-Mental State Exam, Montreal Cognitive Assessment. Secondary outcomes: CDR, UPDRS III, CGI. EEG analysis included theta to beta2 band ratio (TB2R).

Main Results:

  • No significant differences in cognitive or clinical measures between groups.
  • Donepezil treatment group showed a significant decrease in bilateral frontotemporoparietal TB2R.
  • EEG spectral power ratio demonstrated a significant modulatory effect of donepezil.

Conclusions:

  • Donepezil did not improve cognitive function in PD-MCI over 48 weeks.
  • Donepezil treatment modulated EEG patterns in PD-MCI patients.
  • EEG may serve as a sensitive biomarker for treatment response in PD-MCI.

More Related Videos

Transcranial Pulse Stimulation for Alzheimer's Patients06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

1.6K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.3K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
740
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
565
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
305
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
285